LOS ANGELES, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”) today announced the successful completion of its 3rd engineering batch of BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 at its U.S. manufacturing site.
View original post here:
Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
Jonathan Milner releases presentation to Abcam plc shareholders, outlining reasons to reject Danaher's bid and strategic vision for the Company
Jonathan Milner Issues Statement Responding to ISS Report
More here:
Jonathan Milner Issues Statement Responding to ISS Report
- Notable expects to initiate trading on the Nasdaq Capital Market under ticker symbol “NTBL” effective at market open on October 17 -
Visit link:
Notable Labs Closes Merger Transaction With VBL Therapeutics
MBX 2109 was generally well-tolerated across all dosing cohorts
Partnership supports execution of a large phase 2 global study to evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS.
Call scheduled for Tuesday, October 17, 2023 at 8:00 a.m. ET Call scheduled for Tuesday, October 17, 2023 at 8:00 a.m. ET
See the original post here:
Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures
Naxitamab-based chemo-immunotherapy significantly improves long-term outcomes when administered early during the course of treatment Naxitamab-based chemo-immunotherapy significantly improves long-term outcomes when administered early during the course of treatment
See original here:
Y-mAbs Announces Publication in Cancers
— 52-week results from the Phase 3 PaTHway Trial showed that the skeletal dynamics of adult patients with chronic hypoparathyroidism treated with TransCon PTH trended toward a new steady state closer to age-appropriate norms
See the original post:
Ascendis Pharma Presents TransCon™ PTH (palopegteriparatide) Phase 3 52-Week Skeletal Dynamics Data at ASBMR 2023